Mitsubishi Tanabe Logs Record Sales, but Profits Sag on Higher R&D/SGA Costs

Mitsubishi Tanabe Pharma chalked up a record revenue in FY2017 thanks to its stand-alone sales in the US, but saw double-digit drops on the profit front as it saw higher R&D outlays and an increase in SGA costs following the...read more